Mironid
Mironid seeks to become the world leader in cell signaling directed therapeutic development. The Glasgow-based company is building a pipeline of drug development programs that are targeted at cAMP degrading phosphodiesterase enzymes. These will generate novel and differentiated therapies for a range of diseases with high unmet medical need.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Active
Website
www.mironid.com
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.